Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

Bone

Volumn 45, Issue 5, 2009, Pages 898-902

  Johannesen, Jesper ^a   Briody, Julie ^a   McQuade, Mary ^a   Little, David G ^a,b   Cowell, Christopher T ^a,b   Munns, Craig F ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Avascular necrosis; Bisphosphonates; Bone densitometry; Bone turnover markers; Paediatrics

Indexed keywords

CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

ADOLESCENT; ARTICLE; BODY MASS; BONE AGE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR HEAD NECROSIS; HUMAN; MALE; MINERAL METABOLISM; MORPHOMETRICS; PERTHES DISEASE; RETROSPECTIVE STUDY; SYSTEMIC DISEASE;

ABSORPTIOMETRY, PHOTON; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; CHILD; COHORT STUDIES; DENSITOMETRY; DIPHOSPHONATES; EPIPHYSES; FEMALE; HUMANS; IMIDAZOLES; LEGG-PERTHES DISEASE; MALE; RETROSPECTIVE STUDIES; WOUNDS AND INJURIES;

EID: 70349287542     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.04.255     Document Type: Article

References (30)

1. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 12 Suppl (2000) 2961-2978
2. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119 Suppl 2 (2007) S150-S162
3. Munns C.F., Rauch F., Travers R., and Glorieux F.H. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J. Bone Miner. Res. 20 (2005) 1235-1243
4. Rauch F., Plotkin H., Zeitlin L., and Glorieux F.H. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J. Bone Miner. Res. 18 (2003) 610-614
5. Glorieux F.H., Bishop N.J., Plotkin H., et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339 (1998) 947-952
6. Ward K., Cowell C.T., and Little D.G. Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 36 (2005) 999-1002
7. Ward L., Tricco A.C., Phuong P., et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst. Rev. 4 (2007) CD005324
8. Little D.G., Peat R.A., McEvoy A., et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J. Bone Miner. Res. 18 (2003) 2016-2022
9. Kim H.K., Randall T.S., Bian H., et al. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J. Bone Joint Surg., Am. Vol. 87 (2005) 550-557
10. Ramachandran M., Ward K., Brown R.R., et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J. Bone Joint Surg., Am. Vol. 89 (2007) 1727-1734
11. Munns C.F., Rajab M.H., Hong J., et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 41 (2007) 366-370
12. Land C., Rauch F., and Glorieux F.H. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J. Bone Miner. Res. 21 (2006) 374-379
13. Whyte M.P., Wenkert D., Clements K.L., et al. Bisphosphonate-induced osteopetrosis.[see comment]. N. Engl. J. Med. 349 (2003) 457-463
14. Munns C.F., and Cowell C.T. Prevention and treatment of osteoporosis in chronically ill children. J. Musculoskelet Neuronal Interact 5 (2005) 262-272
15. Kuczmarski R.J., Ogden C.L., Grummer-Strawn L.M., et al. CDC growth charts: United States. Adv. Data 314 (2000) 1-27
16. Lu P.W., Briody J.N., Ogle G.D., et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J. Bone Miner. Res. 9 (1994) 1451-1458
17. Ogle G.D., Allen J.R., Humphries I.R., et al. Body-composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26 y. Am. J. Clin. Nutr. 61 (1995) 746-753
18. Hogler W., Briody J., Woodhead H.J., et al. Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J. Pediatr. 143 (2003) 81-88
19. Greulich W., and Pyle S. Radiographic Atlas of Skeletal Development of the Hand and Wrist (1959), Stanford, Standford University Press 1
20. Spencer R., Sagel S., and Garn S. Age changes in 5 parameters of metacarpal growth. Invest. Radiol. 3 (1968) 27-34
21. Amanat N., Brown R., Bilston L.E., and Little D.G. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J. Orthop. Res. 23 (2005) 1029-1034
22. Little D.G., Cornell M.S., Briody J., et al. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J. Bone Joint Surg., Brit. Vol. 83 (2001) 1069-1074
23. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J. Bone Joint Surg., Am. Vol. 87 (2005) 2155-2159
24. Agarwala S., Jain D., Joshi V.R., and Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology 44 (2005) 352-359
25. Lepola V.T., Hannuniemi R., Kippo K., et al. Long-term effects of clodronate on growing rat bone. Bone 18 (1996) 191-196
26. Unal E., Abaci A., Bober E., and Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J. Pediatr. Endocrinol. 19 (2006) 523-528
27. Zeitlin L., Rauch F., Plotkin H., and Glorieux F.H. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111 (2003) 1030-1036
28. Kim H.K., Sanders M., Athavale S., et al. Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone 39 (2006) 205-212
29. Rauch F., Munns C., Land C., and Glorieux F.H. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J. Clin. Endocrinol. Metab. 91 (2006) 1268-1274
30. Whyte M.P., McAlister W.H., Novack D.V., et al. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J. Bone Miner. Res. 23 10 (2008) 1698-1707 (28 Oct)